c-Fms

CSF-1 receptor; colony stimulating factor 1 receptor; CSF-1R; CSF1R

c-Fms

Related Products

c-FMS (CSF1R, CSF-1R) is a receptor protein-tyrosine kinase of the platelet-derived growth factor receptor (PDGFR) family. c-FMS is the cell surface receptor for IL-34 and CSF1. c-FMS has important roles in haematopoiesis, regulation of proliferation, cell survival and maturation of microglia and monocytes, as well as in controlling the overall immune response.

c-FMS is specifically expressed in osteoclasts and myelomonocytic-lineage cells, such as monocytes and macrophages, and the activation of c-FMS signaling promotes the proliferation or differentiation of these cells. It also promotes the production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL6).

c-Fms Related Products (83)
Recombinant Proteins (20)
Antibodies (1)

By Effects:	Inhibitors (75) Antagonist (1) Chemical (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-12768A

Sotuletinib hydrochloride	Inhibitor	98.84%
Sotuletinib (BLZ945) hydrochloride is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC₅₀ of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs.

HY-124526

Chiauranib	Inhibitor	99.28%
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, VEGFR3/Flt-4, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC₅₀ values ranging from 1-9 nM. Chiauranib has strongly anticancer effects.

HY-10408

Ki20227	Inhibitor	99.17%
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC₅₀s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2/KDR/Flk-1 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction.

HY-117244

AZD7507	Inhibitor	99.45%
AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.

HY-P99031

Mavrilimumab	Inhibitor	98.37%
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death.

HY-10204

OSI-930	Inhibitor	98.57%
OSI-930 is an orally selective inhibitor of Kit, VEGFR2/KDR/Flk-1 and CSF-1R (c-Fms) with IC₅₀s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity.

HY-132935

BPR1R024	Inhibitor	99.06%
BPR1R024 is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 has potent CSF1R inhibition activity with an IC₅₀ value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology.

HY-101774

CSF1R-IN-1	Inhibitor	98.11%
CSF1R-IN-1 is a CSF1R inhibitor with an with an IC₅₀ of 0.5 nM.

HY-153920

Pimicotinib	Inhibitor	99.69%
Pimicotinib is a CSF1R inhibitor with antitumor activity.

HY-112451

cFMS Receptor Inhibitor II	Inhibitor	99.80%
cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor. CSF-1 is a cytokine.

HY-139990

CSF1R-IN-3	Inhibitor	98.26%
CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC₅₀=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity.

HY-P99259

Cabiralizumab	Inhibitor	99.59%
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research.

HY-122906

JTE-952	Inhibitor	99.95%
JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC₅₀ values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis.

HY-119942

c-Fms-IN-8	Inhibitor	99.47%
c-Fms-IN-8 (compound 4a) is a colony stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor, with an IC₅₀ of 9.1 nM.

HY-P99795

Otilimab	Inhibitor
Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor.

HY-18787

c-Fms-IN-2	Inhibitor	99.49%
c-Fms-IN-2 is a FMS kinase inhibitor with an IC₅₀ of 0.024 μM.

HY-101526

GENZ-882706	Inhibitor
GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.

HY-P99452

Axatilimab	Inhibitor	99.59%
Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases.

HY-148181

c-Fms-IN-13	Inhibitor	99.27%
c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor with an IC₅₀ value of 17 nM. c-Fms-IN-13 can be used as an anti-inflammatory agent.

HY-13075

c-Fms-IN-3	Inhibitor	99.69%
c-Fms-IN-3 is a novel c-Fms kinase inhibitor with a potential as anti-inflammatory agent and antirheumatic agent.

Name
Email *

	Sorry, but the email address you supplied was invalid.

c-Fms

c-Fms

c-Fms Related Products (83)

Recombinant Proteins (20)

Antibodies (1)

c-Fms Related Products (83):